Plasma Thrombomodulin Levels and Ischemic Stroke
Authors:
- Zhengbao ZhuZhengbao Zhu
- Daoxia GuoDGDaoxia Guo
- Yiming JiaYJYiming Jia
- Kaixin ZhangKZKaixin Zhang
- Mengyao ShiMSMengyao Shi
- Yanbo PengYPYanbo Peng
- Pinni YangPYPinni Yang
- Jing ChenJCJing Chen
- Jintao ZhangJZJintao Zhang
- Aili WangAWAili Wang
- Tan XuTXTan Xu
- Yonghong ZhangYZYonghong Zhang
- 30 August 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (9) , E916-E924
Abstract
Background and Objectives: Thrombomodulin has been suggested to be implicated in ischemic stroke due to its anticoagulant, anti-inflammatory, and cytoprotective properties. We aimed to investigate the associations of plasma thrombomodulin levels with clinical outcomes after ischemic stroke in a multicenter prognostic cohort study. Methods: Our multicenter prognostic cohort study included 3532 Chinese ischemic stroke patients from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death and major disability (modified Rankin scale [mRS] score ≥3) at 3 months after ischemic stroke. Secondary outcomes included major disability (mRS score, 3-5), vascular events, and the ordered 7-level categorical score of the mRS. Results: During 3 months of follow-up, 867 participants experienced primary outcome. After multivariate adjustment, the adjusted odds ratios or hazard ratios associated with highest quartile of plasma thrombomodulin were 0.75 (95% CI, 0.59-0.97; ptrend=0.029) for primary outcome, 0.73 (95% CI, 0.56-0.94; ptrend=0.028) for major disability, and 0.80 (95% CI, 0.42-1.51; ptrend=0.232) for vascular events. In addition, a significantly better shift in the distribution of mRS score was observed with higher thrombomodulin quartiles (ptrend=0.005). Multivariable-adjusted spline regression model showed a linear relationship between plasma thrombomodulin and the risk of primary outcome (p for linearity=0.027). Subgroup analyses further confirmed these associations. Discussion: Increased plasma thrombomodulin levels at baseline were associated with decreased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting a protective role of thrombomodulin in the development of ischemic stroke. Further studies from various populations are needed to replicate our findings.Keywords
This publication has 26 references indexed in Scilit:
- Statistical Analysis of the Primary Outcome in Acute Stroke TrialsStroke, 2012
- Neuropathologic evidence of endothelial changes in cerebral small vessel diseaseNeurology, 2012
- Solulin reduces infarct volume and regulates gene-expression in transient middle cerebral artery occlusion in ratsBMC Neuroscience, 2011
- The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke modelJournal of Thrombosis and Haemostasis, 2011
- Soluble Thrombomodulin and Brain InfarctionStroke, 2004
- Significance of serum soluble thrombomodulin level in acute cerebral infarctionEuropean Journal of Neurology, 2004
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- Human thrombomodulin: complete cDNA sequence and chromosome localization of the geneBiochemistry, 1987